Translation Acceleration Grant 2017

Movember Translation Acceleration Grant

Prostate Cancer Canada (PCC) invites applications for investigator-initiated Movember Translation Acceleration Grants (TAG) that address a significant issue in the management of prostate cancer. The intent of this program is not to support new discovery. Rather proposals should leverage existing knowledge and capabilities to accelerate impact without overlapping currently funded Prostate Cancer Canada and Movember initiatives.

While the area of prostate cancer covered by the proposal is open, the emphasis of this funding opportunity is to develop an intervention that can be further studied first-in-man, in the form of an interventional or observational study immediately following the funding period. It is expected that a multidisciplinary and multi-institutional approach will be required and each application may consist of independent investigators based in multiple institutions with a lead Principal Investigator. This competition is open to projects studying any stage of the prostate cancer journey but PCC will only consider projects that are completely focused on prostate cancer.
 
This opportunity is awarded by Prostate Cancer Canada and proudly funded by the Movember Foundation.
smaller-still.jpg
 
Award amount: up to $1,500,000 over 3 years

Key dates:
Registration Deadline: December 21, 2016 at 5:00 p.m. Eastern
Full Application Deadline: January 31, 2017 at 5:00 p.m. Eastern
Funding Start Date: April 1, 2017

The online application is available at https://pccgrants.smartsimple.ca  
Movember Translation Acceleration Grant (updated December 21, 2016) RFA document
FAQs and Tipsheet

 
For more information, contact:
 
Jenna Fong, PhD
Manager, Research
416 - 441-2131, Ext. 243

jenna.fong@prostatecancer.ca

 

Joanne Reynolds
Manager, Research Operations
416-441-2131, Ext. 226
joanne.reynolds@prostatecancer.ca
 
 




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

(TORONTO, Canada - Aug 7, 2017) -- Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50% of patient tumour samples.
More

Movember Foundation and Prostate Cancer Canada team up to turn research into results

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
More

Plaid for Dad participation skyrockets in third year

July 7, 2017 - TORONTO, ON - Launched for the first time in 2015, Prostate Cancer Canada's (PCC) Plaid for Dad campaign has further established itself as the way Canadians are choosing to give back on Father's Day weekend.
More


Click here for news archive